dr. karmali on the toxicity profile of ibrutinib maintenance in mcl
Published 5 years ago • 77 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:11
dr. karmali on next steps of research regarding ibrutinib maintenance in mcl
-
2:20
dr. karmali on ibrutinib maintenance following induction in untreated mcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:21
dr. karmali on optimizing maintenance therapy in older patients with mcl
-
0:50
dr. karmali on treating older patients with mcl in the rituximab era
-
1:31
dr. karmali on challenges in mcl
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
-
0:59
dr. karmali on limitations of intensive therapy in older/medically unfit patients with mcl
-
1:24
dr. karmali on novel agents in relapsed/refractory mcl
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
0:51
dr. seymour on role of ibrutinib in cll
-
1:58
dr. shah compares toxicity profiles of ibrutinib and acalabrutinib
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl
-
1:25
dr. goy discusses single-agent ibrutinib in mcl
-
1:46
dr. o'connor on acalabrutinib versus ibrutinib in mcl
-
4:02
managing ibrutinib toxicity in cll